Renova Therapeutics expands intellectual property portfolio

 

Privately-held US biotech firm Renova Therapeutics says it has obtained an exclusive worldwide license to several patents from the non-profit Research Development Foundation (RDF).

This group of patents adds to Renova Therapeutics’ extensive intellectual property portfolio in the cardiovascular and metabolic disease space, paving the way for its­ paracrine gene therapy product pipeline.

RDF and Renova Therapeutics have entered into a worldwide exclusive license agreement for RDF’s portfolio of urocortin and stresscopin genes, as well as select peptides and proteins. Financial terms of the transaction were not revealed.

Subscribe to get the latest news